These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6383417)

  • 1. Treatment of multiple rejection episodes with ALG or ATGAM after cadaveric renal transplantation.
    Toledo-Pereya LH; Whitten J; Baskin S; McNichol L; Thavarajah K; Lin W
    Bol Asoc Med P R; 1984 Jul; 76(7):293-6. PubMed ID: 6383417
    [No Abstract]   [Full Text] [Related]  

  • 2. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S; Alexander JW; Schroeder TJ; First MR
    Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antilymphocyte globulin in cadaveric renal transplantation--a controlled trial.
    Jakobsen A; Sødal G; Flatmark A; Thorsby E
    Scand J Urol Nephrol Suppl; 1977; (42):94-6. PubMed ID: 356233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of steroid-resistant rejections with ATG and/or plasma filtration improves graft survival rates after cadaveric kidney transplantation.
    Fassbinder W; Bechstein PB; Stutte HJ; Scheuermann EH; Hanke P; Knöner M; Dathe G; Jonas D; Schoeppe W
    Neth J Med; 1985; 28(6):265-7. PubMed ID: 3892329
    [No Abstract]   [Full Text] [Related]  

  • 5. Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin.
    Indudhara R; Novick AC; Hodge E; Goormastic M; Papajcik D; Mastroianni B; Cook D
    Urology; 1996 Jun; 47(6):807-12. PubMed ID: 8677568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canadian clinical trial of antilymphocyte globulin in human cadaver renal transplantation.
    Taylor HE; Ackman CF; Horowitz I
    Can Med Assoc J; 1976 Dec; 115(12):1205-8. PubMed ID: 793705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous antilymphocyte globulin in human cadaveric renal allotransplantation. Clinical and immunologic observations.
    Collste LG
    Acta Chir Scand; 1972; 138(8):765-74. PubMed ID: 4565721
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical uses of anti-thymocyte globulin (ATGAM), Part I.
    Gilbert C
    N C Med J; 1984 Nov; 45(11):737-9. PubMed ID: 6392893
    [No Abstract]   [Full Text] [Related]  

  • 9. A prospective randomized comparison of antilymphoblast globulin versus antithymocyte globulin for cadaver kidney transplantation.
    Toledo-Pereyra LH; Bergren C; Mittal VK; Whitten JI; Baskin S; McNichol L
    Transplantation; 1985 Oct; 40(4):448-50. PubMed ID: 3901446
    [No Abstract]   [Full Text] [Related]  

  • 10. Superior renal allograft survival and decreased rejection with early high-dose and sequential multi-species antilymphocyte globulin therapy.
    Thomas F; Cunningham P; Thomas J; Gross U; Gaskins D; Sash C; Parker K
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1874-8. PubMed ID: 3547892
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical significance of immunological findings for the survival time of kidney transplants with antilymphocyte globulin therapy].
    Bullinger W; Hammer C; Land W; Welter H
    Chir Forum Exp Klin Forsch; 1979; ():319-24. PubMed ID: 378592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized prospective clinical trial of antilymphocyte globulin in 100 cadaveric renal transplants.
    Sansom JR; Barnes AD; Hall CL
    Postgrad Med J; 1976; 52(5 Suppl):75-8. PubMed ID: 792851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cadaveric renal transplantation in patients over 55 years of age with special emphasis on immunosuppressive therapy.
    Lundgren G; Fehrman I; Gunnarsson R; Lindholm B; Tillegård A; Ost L; Groth CG
    Transplant Proc; 1982 Sep; 14(3):601-4. PubMed ID: 6758244
    [No Abstract]   [Full Text] [Related]  

  • 14. Individualized monitoring and modulation of immune reactivity using standardized antithymocyte globulin (ATG).
    Thomas F; Mendez-Picon G; Thomas J; Lee HM
    Transplant Proc; 1979 Jun; 11(2):1429-30. PubMed ID: 382531
    [No Abstract]   [Full Text] [Related]  

  • 15. A controlled trial with AHLG Behring: lack of effect on cadaveric renal graft survival.
    Jakobsen A; Flatmark A; Lundgren G; Solheim B; Groth CG
    Scand J Urol Nephrol Suppl; 1981; 64():205-12. PubMed ID: 6755682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction therapy with antithymocyte globulin reduces the incidence of allograft rejection and improves graft survival in cadaver renal transplantation.
    Abouna GM; Kumar MS; Stephan R; Prior JE; Lyons P; Bulova SI; al-Abdullah IH
    Transplant Proc; 1993 Jun; 25(3):2241-2. PubMed ID: 8516886
    [No Abstract]   [Full Text] [Related]  

  • 17. Antilymphocyte globulin (ALG) reverses "irreversible" allograft rejection.
    Light JA; Alijani MR; Biggers JA; Oddenino K; Reinmuth B
    Transplant Proc; 1981 Mar; 13(1 Pt 1):475-81. PubMed ID: 7022877
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment with antilymphocyte globulin (ALG) and evolution of renal transplant: observations of 42 cases].
    Civati G; Grillo C; Di Belgioioso GB; Rovati C; Surian M; Busnach G; Broggi L; Ferrari L
    Boll Ist Sieroter Milan; 1978 May; 57(2):165-72. PubMed ID: 365193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of monoclonal antibodies to T cells (OKT3) for treatment of acute cellular rejection after renal transplantation.
    Birkeland SA; Svendsen V; Rohr N; Hansen BL; Elbirk A; Foged N; Køhler F
    Transplant Proc; 1988 Jun; 20(3):451-4. PubMed ID: 3289183
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of antilymphocyte globulin in renal allograft rejection. A controlled study.
    Birkeland SA
    Postgrad Med J; 1976; 52(5 Suppl):82-8. PubMed ID: 792853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.